Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ivermectin studies
Meta analysis
Home COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 86% Improvement Relative Risk Progression 57% Recovery 94% Recovery (b) 39% Recovery (c) 96% Time to recovery 27% primary Viral clearance 39% Ivermectin  Mahmud et al.  EARLY TREATMENT  DB RCT Is early treatment with ivermectin + doxycycline beneficial for COVID-19? Double-blind RCT 366 patients in Bangladesh (Jun - Aug 2020) Lower progression (p=0.001) and improved recovery (p<0.0001) Mahmud et al., J. Int. Medical Research, Oct 2020 Favors ivermectin Favors control

Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial

Mahmud et al., Journal of International Medical Research, doi:10.5061/dryad.qjq2bvqf6 (date from preprint), NCT04523831
Oct 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. 183 treatment and 183 control patients with no deaths in the treatment arm vs. 3 in the control arm (the 3 control deaths are not included in the analysis of other outcomes). Results may reflect the use of ivermectin, doxycycline, and potential synergistic effects of the combination. In the PRINCIPLE trial, no mortality benefit was seen for doxycycline alone (0.6% mortality with doxycycline vs. 0.2% control).
This is the 6th of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 11th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
risk of death, 85.7% lower, HR 0.14, p = 0.25, treatment 0 of 183 (0.0%), control 3 of 183 (1.6%), NNT 61, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of progression, 57.0% lower, HR 0.43, p < 0.001, treatment 16 of 183 (8.7%), control 32 of 180 (17.8%), NNT 11, adjusted per study, Cox regression.
risk of no recovery, 94.0% lower, HR 0.06, p < 0.001, treatment 72 of 183 (39.3%), control 100 of 180 (55.6%), NNT 6.2, adjusted per study, day 7, Cox regression.
risk of no recovery, 38.5% lower, RR 0.61, p = 0.005, treatment 40 of 183 (21.9%), control 64 of 180 (35.6%), NNT 7.3, day 11.
risk of no recovery, 96.0% lower, HR 0.04, p < 0.001, treatment 42 of 183 (23.0%), control 67 of 180 (37.2%), NNT 7.0, adjusted per study, day 12, Cox regression.
time to recovery, 27.0% lower, HR 0.73, p = 0.003, treatment 183, control 180, Cox regression, primary outcome.
risk of no viral clearance, 39.0% lower, HR 0.61, p = 0.002, treatment 14 of 183 (7.7%), control 36 of 180 (20.0%), NNT 8.1, adjusted per study, Cox regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mahmud et al., 9 Oct 2020, Double Blind Randomized Controlled Trial, Bangladesh, peer-reviewed, 15 authors, study period 1 June, 2020 - 30 August, 2020, average treatment delay 4.0 days, dosage 12mg single dose, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary, trial NCT04523831 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial
Reaz Mahmud, Md. Mujibur Rahman, Iftikher Alam, Kazi Gias Uddin Ahmed, A K M Humayon Kabir, S K Jakaria Been Sayeed, Mohammad Aftab Rassel, Farhana Binte Monayem, Md Shahidul Islam, Mohammad Monirul Islam, Anindita Das Barshan, Mohammad Mahfuzul Hoque, MD Md. Uzzal Mallik, Mohammad Abdullah Yusuf, Mohammad Zaid Hossain
Journal of International Medical Research, doi:10.1177/03000605211013550
Objective: We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection. Methods: This was a randomized, blinded, placebo-controlled trial in patients with mild-tomoderate COVID-19 symptoms randomly assigned to treatment (n ¼ 200) and placebo (n ¼ 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR.
Declaration of conflicting interest The authors declare that there is no conflict of interest. Popular Pharmaceuticals Limited, Bangladesh provided ivermectin, doxycycline, and placebo. The company was not involved in the planning or design of the study and had no role in the collection, analysis, or interpretation of the data. Author contributions Appendix
Beigel, Tomashek, Dodd, ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19 -Preliminary Report, N Engl J Med, doi:10.1056/NEJMoa2007764
Caly, Druce, Catton, The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Canga, Prieto, Li Ebana Mjd, The pharmacokinetics and interactions of ivermectin in humans-a mini-review, AAPS J
Canga, Sahag Un Prieto, Li Ebana, The pharmacokinetics and interactions of ivermectin in humans-a mini-review, AAPS J, doi:10.1208/s12248-007-9000-9
Charan, Biswas, How to calculate sample size for different study designs in medical research?, Indian J Psychol Med, doi:10.4103/0253-7176.116232
Corona Virus, COVID-19
Fiolet, Guihur, Rebeaud, Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.08.022
Gralinski, Baric, Molecular pathology of emerging coronavirus infections, J Pathol, doi:10.1002/path.4454
Griffin, Fricovsky, Ceballos, Tetracycline: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature, Am J Physiol Cell Physiol
Henehan, Montuno, Benedetto, Doxycycline as an anti-inflammatory agent: updates in dermatology, J Eur Acad Dermatol Venereol
Holmes, Pgp, Safety and efficacy review of doxycycline, Clin Med Insights Ther, doi:10.4137/CMT.S2035
Mahmud, Rahman Had, Mahmud, Rahman, Alam et al., access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis
Mckellar, Benchaoui, Avermectins and milbemycins, J Vet Pharmacol Ther
Mehta, Mcauley, Brown, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Metlay, Waterer, Long, Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America, Am J Respir Crit Care Med, doi:10.1164/rccm.201908-1581ST
Phillips, Gallagher, Weiss, Neurovirulent Murine Coronavirus JHM. SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion, J Virol, doi:10.1128/jvi.01564-16
Rodriguez-Morales, Cardona-Ospina, Errez-Ocampo, Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis, Travel Med Infect Dis
Rothan, Bahrani, Mohamed, A combination of doxycycline and ribavirin alleviated chikungunya infection, PLoS One, doi:.10.1371/journal.Pone.0126360
Rothan, Paydar, Inhibitory effect of doxycycline against dengue virus replication in vitro, Arch Virol, doi:10.1007/s00705-013-1880-7
Schmith, Zhou, Lohmer, The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19, Clin Pharmacol Ther, doi:10.1002/cpt.1889
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: a clinical therapeutic staging proposal, J Heart Lung Transplant, doi:10.1016/j.healun.2020.03.012
Skipper, Pastick, Engen, Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial, Ann Intern Med, doi:10.7326/M20-4207
Sodhi, Etminan, Therapeutic potential for tetracycline in the treatment of COVID-19, Pharmacotherapy, doi:10.1002/phar.2395
Spinner, Gottlieb, Criner, Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial, JAMA. Published online, doi:10.1001/jama.2020.16349
Stone, Frigault, Boyd, Efficacy of Tocilizumab in Patients Hospitalized with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2028836
Sundy, Sarah, Chunxiao, The broad spectrum antiviral ivermectin targets the host nuclear transport import in a/b1heterodimer, J Antiviral
Vanlaere, Libert, Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock, Clin Microbiol Rev, doi:10.1128/CMR.00047-08
Who Director, s opening remarks at the media briefing on COVID-19 -11
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop